Celldex Therapeutics Inc.
CLDX
Market Cap$2.28B
Close$
$-4.71
112.2% downside
Current Fair Value
112.2% downsideOvervalued by 112.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.28 Billion |
|---|---|
| Enterprise Value | $1.86 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.92 |
| Beta | 1.04 |
| Outstanding Shares | 55,900,679 |
| Avg 30 Day Volume | 822,037 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -16.15 |
|---|---|
| PEG | -25.44 |
| Price to Sales | - |
| Price to Book Ratio | 5.51 |
| Enterprise Value to Revenue | 270.39 |
| Enterprise Value to EBIT | -13.1 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...